Loading...
XETRSBS
Market cap376mUSD
Dec 23, Last price  
29.75EUR
1D
2.59%
1Q
-31.45%
Jan 2017
-35.03%
Name

Stratec SE

Chart & Performance

D1W1MN
XETR:SBS chart
P/E
27.68
P/S
1.38
EPS
1.07
Div Yield, %
3.26%
Shrs. gr., 5y
0.21%
Rev. gr., 5y
6.88%
Revenues
262m
-4.63%
39,207,23248,415,0910067,527,00079,589,273106,731,999122,196,813122,424,000127,950,000144,860,000146,886,000184,911,000209,764,000187,819,000221,641,000250,099,000287,335,000274,625,000261,911,000
Net income
13m
-55.29%
2,777,9074,412,559009,991,00011,673,58613,039,16315,281,66013,973,00015,478,00019,768,00022,084,00019,572,00025,635,0008,969,00014,440,00025,175,00039,958,00029,223,00013,067,000
CFO
19m
+88.98%
2,406,0001,308,0008,827,0009,567,8804,690,00010,878,0001,448,00010,707,0002,720,00023,837,00039,752,00026,033,00016,256,00029,981,00011,950,00021,262,00031,849,00063,473,00010,279,00019,425,000
Dividend
May 20, 20240.55 EUR/sh
Earnings
May 16, 2025

Profile

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
URL
https://www.stratec.com/
IPO date
Aug 25, 1998
Employees
1,512
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
261,911
-4.63%
274,625
-4.42%
287,335
14.89%
Cost of revenue
237,739
232,261
237,165
Unusual Expense (Income)
NOPBT
24,172
42,364
50,170
NOPBT Margin
9.23%
15.43%
17.46%
Operating Taxes
5,162
9,865
6,874
Tax Rate
21.36%
23.29%
13.70%
NOPAT
19,010
32,499
43,296
Net income
13,067
-55.29%
29,223
-26.87%
39,958
58.72%
Dividends
(11,790)
(11,521)
(10,889)
Dividend yield
Proceeds from repurchase of equity
1,744
1,265
BB yield
Debt
Debt current
47,035
7,084
6,732
Long-term debt
110,667
93,591
88,023
Deferred revenue
24,181
15,477
19,164
Other long-term liabilities
21,182
7,120
10,584
Net debt
120,587
74,468
43,996
Cash flow
Cash from operating activities
19,425
10,279
63,473
CAPEX
(8,342)
(19,019)
(20,232)
Cash from investing activities
(44,155)
(18,997)
(20,127)
Cash from financing activities
35,442
(14,105)
(34,329)
FCF
(30,254)
(5,632)
26,289
Balance
Cash
34,215
24,072
48,722
Long term investments
2,900
2,135
2,037
Excess cash
24,019
12,476
36,392
Stockholders' equity
176,866
190,074
173,577
Invested Capital
383,088
311,181
279,818
ROIC
5.48%
11.00%
15.91%
ROCE
5.79%
12.72%
15.44%
EV
Common stock shares outstanding
12,159
12,173
12,181
Price
Market cap
EV
EBITDA
41,865
59,295
68,424
EV/EBITDA
Interest
3,992
1,898
1,431
Interest/NOPBT
16.51%
4.48%
2.85%